Emergent BioSolutions (EBS) Total Liabilities (2010 - 2026)

Emergent BioSolutions' Total Liabilities history runs 17 years deep, the most recent figure standing at $797.3 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 8.71% year-over-year to $797.3 million; the TTM figure through Mar 2026 stood at $797.3 million (down 8.71% YoY), while the FY2025 annual figure was $796.0 million, down 12.23% from the prior year.
• Total Liabilities was $797.3 million for Q1 2026 at Emergent BioSolutions, roughly flat from $796.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.8 billion in Q4 2022 to a low of $796.0 million in Q4 2025.
• Historically, Total Liabilities has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities surged 44.98% in 2023, then plunged 34.77% in 2024.
• A 5-year view of Total Liabilities shows it stood at $1.8 billion in 2022, then plunged by 34.0% to $1.2 billion in 2023, then retreated by 22.74% to $906.9 million in 2024, then fell by 12.23% to $796.0 million in 2025, then advanced by 0.16% to $797.3 million in 2026.
• The last three Total Liabilities figures came in at $797.3 million (Q1 2026), $796.0 million (Q4 2025), and $878.5 million (Q3 2025), per Business Quant data.